Wrapping up 2023: A recap of top biotech moments of this year
From advancements in Alzheimer's disease treatments to new approaches in cancer therapy, artificial intelligence (AI) progression, and obesity ...
CAR Macrophage therapy
Immunotherapy, which leverages the body’s immune system to fight cancer, had a few ups and downs in 2023. This approach offers a promising alternative for patients who may not respond to conventional treatments. As current approaches struggle with solid tumors, <anchor>CAR Macrophage therapy</anchor> could embody new hopes for oncology.
CAR macrophage therapy: a promising approach in cancer care
CAR macrophage therapy: a promising approach in cancer care

[Skip to content](#primary)

Search for:

Suggested Topics:

[![Labiotech.eu](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)](https://www.labiotech.eu/)

- Categories




Browse by resource or article category





## Resources



- [Reports](/reports/)
- [Podcasts](/podcast/)
- [Expert Advice](/expert-advice/)
- [List of biotech events](/biotech-conferences-and-events-2024/)
- [Biotech funding tracker](/recent-biotech-fundings/)
- [Biotech deals tracker](https://www.labiotech.eu/recent-biotech-deals/)

## Categories

- [News and Trends](/trends-news/)
- [In-depth](/in-depth/)
- [Best in Biotech](/best-biotech/)
- [Opinion](/opinion/)
- [Sponsored](/partner/)

[![Swiss biotech companies](https://www.labiotech.eu/wp-content/uploads/2021/06/alchemyrefiner-alchemymagic-3-1284d72a-247c-4461-8f19-c0a5acf74a12-0-1024x532.jpg)**Swiss biotech going strong in 2024: 18 companies to put on your radar**](/best-biotech/biotech-startups-switzerland/)

[![biotech startup funding](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20640%20335%22%3E%3C/svg%3E) **The ABC of biotech startup funding**](/expert-advice/biotech-startup-funding/)

- Sectors




Browse by sector





## Approaches



- [Antibody](/tag/antibodies/)
- [Artificial Intelligence](/tag/artificial-intelligence/)
- [CAR-T](/tag/car-t/)
- [Cell Therapy](/tag/cell-therapy/)
- [CRISPR](/tag/crispr/)

- [Gene editing](/tag/gene-editing/)
- [Gene therapy](/tag/gene-therapy/)
- [Genomics](/tag/genomics/)
- [Microbiome](/tag/microbiome/)
- [mRNA Technology](/tag/mrna-technology/)
- [T-cells](/tag/t-cells/)

## Therapeutic areas

- [Aging](/tag/anti-aging/)
- [Alzheimer's](/tag/alzheimers/)
- [Cancer](/tag/cancer/)
- [Diabetes](/tag/diabetes/)
- [Mental health](/tag/mental-health-issues/)

[![Bridge RNA](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20640%20333%22%3E%3C/svg%3E) **Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR**](/in-depth/bridge-rna-gene-editing/)

[![Biotechnology sports performance](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20640%20426%22%3E%3C/svg%3E) **Special Olympics: How is biotechnology revolutionizing sports performance worldwide?**](/in-depth/biotechnology-sports-performance/)

- Drug Development




Stay informed on the latest drug development updates





## R&D



- [Research](/tag/research/)
- [Drug Discovery](/tag/drug-discovery/)
- [Clinical trials](/tag/clinical-trial/)
- [Regulatory approval](/tag/regulatory-approval/)

## BD

- [Funding](/tag/funding/)
- [Partnerships](/tag/collaboration-deals/)
- [M&A](/tag/merger-acquisition/)
- [Top biotech startups](/tag/biotech-startup/)

## World biotech leaders

- [USA](/tag/usa/)
- [U.K.](/tag/united-kingdom/)
- [France](/tag/france/)
- [Germany](/tag/germany/)

[![Accelerators Startups partnership relationship academia investor Elena Resko 3](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20640%20335%22%3E%3C/svg%3E) **Connect with decision-makers and researchers worldwide for collaborative opportunities**](https://app.in-part.com/register?utm_source=labiotech&utm_campaign=Labiotech%20Megamenu%202024&utm_medium=megamenu)

- More




Learn more about Labiotech





## Company



- [About Us](/about-us/)
- [Our Editorial Calendar](/labiotech-biotech-editorial-calendar/)
- [Careers](/join-us/)
- [About our parent company Inpart](https://www.inpart.io/company?utm_source=labiotech&utm_campaign=Labiotech%20Megamenu%202024&utm_medium=megamenu)

## Join Us

- [Contact Us](/contact/)

[![Subscribe to our newsletter](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20600%20400%22%3E%3C/svg%3E) **Subscribe to our newsletter**](/newsletter/)

[![biotech funding money business oncology neurology](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20640%20221%22%3E%3C/svg%3E) **Advertise with us**](https://www.labiotech.eu/advertise/)

[![](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)](https://app.in-part.com/register?utm_campaign=Labiotech&utm_source=Labiotech&utm_medium=website%20banner&utm_content=network)![](data:image/gif;base64,R0lGODlhAQABAIAAAP///////yH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)

[![Subscribe to our newsletter](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)](/newsletter/)

[![Labiotech.eu](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)](https://www.labiotech.eu/)

[Subscribe](/newsletter/)

Search for:

## Top Topics

[Cancer](https://www.labiotech.eu/tag/cancer) [Gene therapy](https://www.labiotech.eu/tag/gene-therapy) [Artificial intelligence](https://www.labiotech.eu/tag/artificial-intelligence) [mRNA technology](https://www.labiotech.eu/tag/mrna-technology) [CRISPR](https://www.labiotech.eu/tag/crispr) [CAR-T](https://www.labiotech.eu/tag/car-t)

- Categories


- Resources
- [Reports](/reports/)
- [Podcasts](/podcast/)
- [Expert Advice](/expert-advice/)
- [List of biotech events](/biotech-conferences-and-events-2024/)
- [Biotech funding tracker](/recent-biotech-fundings/)
- [Biotech deals tracker](https://www.labiotech.eu/recent-biotech-deals/)
- Categories
- [News and Trends](/trends-news/)
- [In-depth](/in-depth/)
- [Best in Biotech](/best-biotech/)
- [Opinion](/opinion/)
- [Sponsored](/partner/)

[![Swiss biotech companies](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20300%20156%22%3E%3C/svg%3E) **Swiss biotech going strong in 2024: 18 companies to put on your radar**](/best-biotech/biotech-startups-switzerland/)

[![biotech startup funding](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20300%20157%22%3E%3C/svg%3E) **The ABC of biotech startup funding**](/expert-advice/biotech-startup-funding/)

- Sectors


- Approaches
- [Antibody](/tag/antibodies/)
- [Artificial Intelligence](/tag/artificial-intelligence/)
- [CAR-T](/tag/car-t/)
- [Cell Therapy](/tag/cell-therapy/)
- [CRISPR](/tag/crispr/)
- [Gene editing](/tag/gene-editing/)
- [Gene therapy](/tag/gene-therapy/)
- [Genomics](/tag/genomics/)
- [Microbiome](/tag/microbiome/)
- [mRNA Technology](/tag/mrna-technology/)
- [T-cells](/tag/t-cells/)
- Therapeutic areas
- [Aging](/tag/anti-aging/)
- [Alzheimer's](/tag/alzheimers/)
- [Cancer](/tag/cancer/)
- [Diabetes](/tag/diabetes/)
- [Mental health](/tag/mental-health-issues/)

[![Bridge RNA](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20300%20156%22%3E%3C/svg%3E) **Bridge RNA: A new gene editing technique that could overcome the limitations of CRISPR**](/in-depth/bridge-rna-gene-editing/)

[![Biotechnology sports performance](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20300%20200%22%3E%3C/svg%3E) **Special Olympics: How is biotechnology revolutionizing sports performance worldwide?**](/in-depth/biotechnology-sports-performance/)

- Drug Development


- R&D
- [Research](/tag/research/)
- [Drug Discovery](/tag/drug-discovery/)
- [Clinical trials](/tag/clinical-trial/)
- [Regulatory approval](/tag/regulatory-approval/)
- BD
- [Funding](/tag/funding/)
- [Partnerships](/tag/collaboration-deals/)
- [M&A](/tag/merger-acquisition/)
- [Top biotech startups](/tag/biotech-startup/)
- World biotech leaders
- [USA](/tag/usa/)
- [U.K.](/tag/united-kingdom/)
- [France](/tag/france/)
- [Germany](/tag/germany/)

[![Accelerators Startups partnership relationship academia investor Elena Resko 3](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20300%20157%22%3E%3C/svg%3E) **Connect with decision-makers and researchers worldwide for collaborative opportunities**](https://app.in-part.com/register?utm_source=labiotech&utm_campaign=Labiotech%20Megamenu%202024&utm_medium=megamenu)

- More


- Company
- [About Us](/about-us/)
- [Our Editorial Calendar](/labiotech-biotech-editorial-calendar/)
- [Careers](/join-us/)
- [About our parent company Inpart](https://www.inpart.io/company?utm_source=labiotech&utm_campaign=Labiotech%20Megamenu%202024&utm_medium=megamenu)
- Join Us
- [Contact Us](/contact/)

[![Subscribe to our newsletter](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20300%20200%22%3E%3C/svg%3E) **Subscribe to our newsletter**](/newsletter/)

[![biotech funding money business oncology neurology](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20300%20103%22%3E%3C/svg%3E) **Advertise with us**](https://www.labiotech.eu/advertise/)

[Podcast](https://www.labiotech.eu/podcast/) [Reports](https://www.labiotech.eu/reports/)

[Home](https://www.labiotech.eu/)[In Depth](https://www.labiotech.eu/in-depth/)**The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy**

# The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy

![cropped Bio.Picture.Jules scaled 1](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20103%20103%22%3E%3C/svg%3E)

By [Jules Adam](https://www.labiotech.eu/author/jules/)

5 minutesmins

November 23, 2023

5 minutesmins

Share

- [![Share on Whatsapp](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/whatsapp.svg)\
WhatsApp](https://wa.me/?text=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu%20https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)
- [![Share on Twitter](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/twitter.svg)\
Twitter](https://twitter.com/intent/tweet/?text=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&url=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)
- [![Share on Linkedin](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/linkedin.svg)\
Linkedin](https://www.linkedin.com/shareArticle?mini=true&url=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/&title=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&summary=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&source=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)
- [![Email this](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/message.svg)\
Email](mailto:?subject=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&body=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)

Image/Anastasiia Slynko

![Anastasiia Slynko cancer CAR macrophage](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20744%20368%22%3E%3C/svg%3E)

[![Share on Whatsapp](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/whatsapp.svg)](https://wa.me/?text=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu%20https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)[![Share on Twitter](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/twitter.svg)](https://twitter.com/intent/tweet/?text=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&url=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)[![Share on Linkedin](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/linkedin.svg)](https://www.linkedin.com/shareArticle?mini=true&url=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/&title=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&summary=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&source=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)[![Email this](https://www.labiotech.eu/wp-content/themes/labiotechv4/images/message.svg)](mailto:?subject=The next frontier in immunotherapy? CAR-Macrophages as a novel cancer treatment strategy%20on%20Labiotech.eu&body=https://www.labiotech.eu/in-depth/car-macrophage-therapy-cancer/)[![Visit us on Google News](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)](https://news.google.com/publications/CAAiEB6OCDtX4oYu1iW-N8VzVg4qFAgKIhAejgg7V-KGLtYlvjfFc1YO?hl=en-US&gl=US&ceid=US%3Aen)

**Immunotherapy has revolutionized cancer treatment, offering promising avenues beyond traditional methods. Recent breakthroughs showcased at the Society for Immunotherapy of Cancer’s (SITC) annual meeting have spotlighted innovative approaches, notably** [**chimeric antigen receptor macrophage (CAR-M) therapy**](https://carismatx.com/carisma-presents-pre-clinical-proof-of-concept-for-in-vivo-car-m-using-mrna-platform-in-collaboration-with-moderna-at-sitc/) **, offering new strategies in the fight against solid tumors and addressing the limitations of current treatments.**

## **Navigating the labyrinth: immunotherapy’s battle against solid tumors**

[Immunotherapy](https://www.labiotech.eu/best-biotech/cancers-immunotherapy-cure/) has shown remarkable success, especially in treating [blood cancers](https://www.labiotech.eu/interview/natural-killer-cells-treating-blood-cancers/). However, when it comes to solid tumors which occur in breast, lung or pancreatic cancers, the story changes. These masses are proving to be a true challenge for immunotherapy.

[Solid tumors, often dubbed “cold,” are particularly challenging](https://www.labiotech.eu/in-depth/immunotherapy-solid-tumors/). They are harder to detect for the immune system. They are entrenched within the tumor microenvironment (TME) and prevent immune cells from effectively responding. It is an area where conventional treatments, be it checkpoint inhibitors or CAR-T cell therapies, struggle to gain traction.

CAR-T cells have been highly successful in blood cancers but they stumble when faced with solid tumors. The personalized nature of CAR-T therapies, involving a patient-specific cell extraction and reintroduction, isn’t only time-consuming, it also represents significant logistical and financial expenses. Therefore, the widespread access to this treatment is limited.

[Checkpoint inhibitors](https://www.labiotech.eu/infographics/checkpoint-inhibitors-infographic/) have showcased convincing results in reawakening the immune response against solid tumors. However, tumors tend to surpass these therapies by switching up their defenses.

It seems there is a need for new innovative approaches which could overcome these limits. This is where CAR-M therapies come in.

## What is the mechanism of **CAR** macrophage therapy?

Carisma Therapeutics stands at the forefront of this new field. Its focus revolves around redefining strategies to combat solid tumors, notably through the development of CAR-M therapies.

CAR macrophage therapy represents a significant scientific advancement in cancer treatment. This innovation exploits the capabilities of macrophages, empowering them with engineered chimeric antigen receptors (CARs). CAR-M is designed to target tumors with precision, within the tumor microenvironment (TME).

These reprogrammed macrophages can easily infiltrate the TME. Macrophages are an important constitutive element of tumor mass, allowing them to get clearance. Once they are in, they summon tumor-killer cells which, in turn, target the tumor from within. CAR-M acts as an undercover agent to release other immune cells in the TME, as they would usually have much more barriers to entry.

## **CT-0508: Carisma’s encouraging candidate in addressing HER2+ cancers**

Within Carisma’s research portfolio, CT-0508 is a promising contender, showcasing [notable strides in preclinical studies](https://www.prnewswire.com/news-releases/carisma-announces-latest-data-from-phase-1-clinical-trial-of-ct-0508-at-8th-annual-car-tcr-summit-301915405.html) directed at HER2+ cancers. This lead candidate demonstrates potential advancements in targeting specific tumor types, hinting at broader implications across various solid tumors.

In focused studies targeting HER2+ cancers, this solution exhibits promising outcomes, showing improvements in overall survival rates. While these advances primarily focus on a particular cancer subset, the implications extend towards a potential approach for diverse solid tumors.

This candidate lays the groundwork for potential advancements in solid tumor therapies, hinting at a possible future where diverse tumor types might find tailored solutions through similar strategies.

Carisma charts a strategic course towards clinical testing, outlining phase 1 plans for CT-0508’s transition from lab success to real-world application. The impending clinical trials bear the weight of expectations. The completion of the trial is [estimated in December, 2024](https://www.clinicaltrials.gov/study/NCT04660929?intr=%20CT-0508&rank=1). Will CAR macrophage therapy’s mechanisms prove efficient in live settings?

## Suggested Articles

## [Is Latin America becoming an investment hotspot for biotech and deep tech?](https://www.labiotech.eu/in-depth/biotech-deep-tech-investment-latin-america/)

## [Cytokine release syndrome: how pharma is tackling a 21st century disease](https://www.labiotech.eu/in-depth/biotech-tackling-cytokine-release-syndrome/)

## [The biggest private biotech investments in August 2024](https://www.labiotech.eu/in-depth/biotech-investments-august-2024/)

## [The biggest private biotech investments in September 2022](https://www.labiotech.eu/in-depth/biotech-investments-september-2022/)

## [Drug repurposing emerges as viable option for rare disease treatment](https://www.labiotech.eu/in-depth/drug-repurposing-viable-option-rare-disease-treatment/)

## What are the potential applications of CAR-M therapy beyong oncology?

The potential of CAR-M extends beyond oncology. [The concept explores possibilities](https://www.nature.com/articles/s12276-023-01068-z) in addressing neurodegenerative diseases and inflammatory conditions, offering a versatile platform that might extend therapeutic benefits to conditions beyond cancer.

Indeed, macrophages are heterogenous. In addition to their cancer-cells-clearing potential, they have tissue regeneration properties. ClinicalTrials.gov records several trials for macrophages cell therapy. The areas of action are various: pulmonary alveolar proteinosis (PAP) and neurodegenerative diseases are applications which show promise.

In animal trials, only one pulmonary macrophage transplantation resulted in the full treatment of the lung disease. In these trials, the treatment was safe.

The efficacy of stem cell engraftment is limited by the size of the human brain. The field is facing difficulties in the homogeneous distribution of the cells. Still in trial phases, cells derived from macrophages have had promising results in solving this issue. The cells were transferred through a bone marrow transplant, and have allowed a more efficient distribution in the brain.

To reach their objectives in cancer research, [Carisma Therapeutics is already collaborating with industry giant Moderna](https://investors.modernatx.com/news/news-details/2022/Moderna-and-Carisma-Establish-Collaboration-to-Develop-in-vivo-Engineered-Chimeric-Antigen-Receptor-Monocytes-CAR-M-for-Oncology/default.aspx). Under their agreement, Carisma received a $45 million payment, and Moderna made a $35 million investment in the form of a convertible note. Carisma will also receive research funding throughout the collaboration. Carisma Therapeutic remains in charge of the research and development of candidates, while Moderna will take the lead in clinical development and commercialization.

The emergence of CAR-M therapies could mark a significant leap forward in immunotherapy. With Carisma Therapeutics at the forefront, its promising preclinical success and imminent clinical trials of CT-0508, innovative immunotherapies might offer new possibilities in combating solid tumors, and even extend their action to other conditions and diseases.

![inpart logo](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20225%2080%22%3E%3C/svg%3E)

New technologies related to macrophages

- [Optogenetic Fc Receptor for Precise Control Over Macrophage Anti-Cancer Response](https://in-part.co/OGaGQAPxjBz) – University of California, Santa Barbara
- [BG34-200: A Potent Immunotherapeutic for Pancreatic Ductal Adenocarcinoma, Melanoma, Osteosarcoma, and other Solid Tumor Cancers](https://in-part.co/53K3QrRV0ob) – Case Western Reserve University
- [Tools and Methods to Enhance Viability of Antigen-Presenting Cells for Cell-Based Therapy](https://in-part.co/xXGXaLWK0kE) – Institut Carie

Explore other topics:[Cancer](https://www.labiotech.eu/tag/cancer/)[Immunotherapy](https://www.labiotech.eu/tag/immunotherapy/)

[ADVERTISEMENT](/advertise/)

## Newsletter Signup - Under Article / In Page

"\*" indicates required fields

## Subscribe to our newsletter to get the latest biotech news!

Name\*

First NameLast Name

Job title\*

Company name\*

Email\*

Consent\*

I consent to share my personal data with Labiotech UG

We're committed to your privacy. Labiotech uses the information you provide to us to send you updates about promotions, special offers from our partners, and news. You may unsubscribe from these communications at any time. We will not share or sell your personal information. For more information, check out our [Privacy Policy](https://www.labiotech.eu/privacy-policy/).

CAPTCHA

Phone

This field is for validation purposes and should be left unchanged.

![Labiotech.eu](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)

## Latest Articles

## [Stealth mode biotech startups: Everything you need to know](https://www.labiotech.eu/expert-advice/stealth-mode-biotech/)

## [Targeting inflammation: A revolution in disease treatment](https://www.labiotech.eu/podcast/targeting-inflammation-a-revolution-in-disease-treatment/)

## [New treatments being developed for schizophrenia](https://www.labiotech.eu/in-depth/new-treatments-schizophrenia/)

## [Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges](https://www.labiotech.eu/trends-news/rd-crunch-amid-spending-cuts/)

ADVERTISEMENT

[![](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)](https://app.in-part.com/register?utm_campaign=Labiotech&utm_source=Labiotech&utm_medium=website%20banner&utm_content=network)![](data:image/gif;base64,R0lGODlhAQABAIAAAP///////yH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==)

## Suggested Articles

![Space medicine plants](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [Plants Allow Astronauts to Make Medicines in Space](https://www.labiotech.eu/in-depth/space-medicine-plants/)

![Biotech bankruptcies](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [Biotech bankruptcies: what to expect in 2024 following a record year?](https://www.labiotech.eu/in-depth/biotech-bankruptcies-what-to-expect-in-2024-following-a-record-year/)

![Anastasiia Slynko cancer CAR macrophage](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [Navignostics maps tumor proteomes to improve precision oncology](https://www.labiotech.eu/in-depth/navignostics-precision-oncology-proteomics/)

![natural flavors biotech industry](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [How the Biotech Industry Makes Flavors Healthy and Eco-Friendly](https://www.labiotech.eu/in-depth/natural-flavors-biotech-industry/)

![covid 19 coronavirus 1600x460](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [How Has Coronavirus Affected Europe’s Biotech Stocks?](https://www.labiotech.eu/in-depth/biotech-stock-coronavirus/)

## Latest Articles

![Stealth mode biotech startups](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [Stealth mode biotech startups: Everything you need to know](https://www.labiotech.eu/expert-advice/stealth-mode-biotech/)

![](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [Targeting inflammation: A revolution in disease treatment](https://www.labiotech.eu/podcast/targeting-inflammation-a-revolution-in-disease-treatment/)

![Schizophrenia clinical trials](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [New treatments being developed for schizophrenia](https://www.labiotech.eu/in-depth/new-treatments-schizophrenia/)

![Inflation Reduction Act](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20150%20150%22%3E%3C/svg%3E)

## [Biotech R&D crunch: The impact of the Inflation Reduction Act and economic challenges](https://www.labiotech.eu/trends-news/rd-crunch-amid-spending-cuts/)

[![Labiotech.eu](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)](https://www.labiotech.eu/)

### Subscribe to our newsletter to get the latest biotech news!

[Signup now](/newsletter/)

- ### Explore Labiotech


  - [Biotech news by sector](https://www.labiotech.eu/sector-a-z-index/)
  - [Biotech news by region](https://www.labiotech.eu/country-a-z-index/)
  - [Biotech news by company](https://www.labiotech.eu/company-a-z-index/)
  - [News and Trends](https://www.labiotech.eu/trends-news/)
  - [In Depth](https://www.labiotech.eu/in-depth/)
  - [Best in Biotech](https://www.labiotech.eu/best-biotech/)
  - [Reports](/reports/)
  - [Podcast](https://www.labiotech.eu/podcast/)
  - [Site Map](https://www.labiotech.eu/site-map/)
- ### About Labiotech



  - [Advertise with Labiotech.eu](https://www.labiotech.eu/advertise/)
  - [Subscribe](https://www.labiotech.eu/newsletter-4/)
  - [Contact](https://www.labiotech.eu/contact/)
  - [Editorial calendar](https://www.labiotech.eu/labiotech-biotech-editorial-calendar/)

### Our Other Brands

  - [Inpart](https://www.inpart.io/)
- ### Follow Us


  - [![Visit us on Instagram](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)Instagram](https://www.instagram.com/labiotech.eu/?hl=en)
  - [![Visit us on Twitter](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)Twitter](https://twitter.com/Labiotech_eu)
  - [![Visit us on Linkedin](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)Linkedin](https://www.linkedin.com/company/5312453/)
  - [![Visit us on Google News](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)Google News](https://news.google.com/publications/CAAiEB6OCDtX4oYu1iW-N8VzVg4qFAgKIhAejgg7V-KGLtYlvjfFc1YO?hl=en-US&gl=US&ceid=US%3Aen)
  - [![Visit us on Youtube](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)Youtube](https://www.youtube.com/c/LabiotechEu)
  - [![Our RSS Feed](data:image/svg+xml,%3Csvg%20xmlns=%22http://www.w3.org/2000/svg%22%20viewBox=%220%200%20210%20140%22%3E%3C/svg%3E)RSS Feed](/feed/)

## Newsletter Signup - Footer

"\*" indicates required fields

## Subscribe to our newsletter to get the latest biotech news!

Name\*

First NameLast Name

Job title\*

Company name\*

Email\*

Consent\*

I consent to share my personal data with Labiotech UG

CAPTCHA

Email

This field is for validation purposes and should be left unchanged.

Made with -Labiotech UG, All Rights Reserved-

- [Imprint](https://www.labiotech.eu/imprint/)
- [Privacy Policy](https://www.labiotech.eu/privacy-policy/)